Provided by Tiger Trade Technology Pte. Ltd.

California Resources

68.87
+0.91001.34%
Post-market: 68.870.00000.00%19:59 EDT
Volume:915.57K
Turnover:63.10M
Market Cap:6.10B
PE:16.60
High:69.31
Open:68.07
Low:68.05
Close:67.96
52wk High:69.31
52wk Low:30.97
Shares:88.60M
Float Shares:88.50M
Volume Ratio:0.62
T/O Rate:1.03%
Dividend:1.57
Dividend Rate:2.28%
EPS(TTM):4.15
EPS(LYR):4.15
ROE:10.07%
ROA:6.42%
PB:1.66
PE(LYR):16.60

Loading ...

California Resources Corporation Achieves ‘Grade A’ Certification for its San Joaquin Valley Basin Assets

GlobeNewswire
·
Feb 25

FDA grants traditional approval to encorafenib for CRC with BRAF V600E mutation

TIPRANKS
·
Feb 25

MIRXES-B Completes Patient Enrollment for CADENCE CRC Study

Stock News
·
Feb 23

Earning Preview: California Resources Q4 revenue is expected to decrease by 14.00%, and institutional views are mixed-to-cautious

Earnings Agent
·
Feb 23

Daiwa House Restructures U.S. Operations, Establishes CRC Holdings as Specified Subsidiary

TIPRANKS
·
Feb 20

Adagene to Participate in Two Upcoming Investor Conferences

GlobeNewswire
·
Feb 17

High Growth Tech Stocks In The US February 2026

Simply Wall St.
·
Feb 12

Press Release: Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Feb 11

U.S. RESEARCH ROUNDUP-Alphabet, Corteva, Varonis Systems

Reuters
·
Feb 05

California Resources Corp : Gerdes Energy Research Cuts to Neutral From Buy

THOMSON REUTERS
·
Feb 05

FACTBOX-US energy sector deals regain momentum after mid-2025 slowdown

Reuters
·
Feb 03

Ovintiv Appoints Gregory P. Hill to Board of Directors

Reuters
·
Jan 30

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

GlobeNewswire
·
Jan 29

California Resources Is Maintained at Buy by UBS

Dow Jones
·
Jan 27

UBS Adjusts Price Target on California Resources to $63 From $64, Maintains Buy Rating

MT Newswires Live
·
Jan 26

California Resources price target lowered to $63 from $64 at UBS

TIPRANKS
·
Jan 26

Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB

TIPRANKS
·
Jan 24

Press Release: Adagene Provides Business Update and 2026 Objectives

Dow Jones
·
Jan 23

Analysts Offer Insights on Energy Companies: California Resources Corp (CRC) and Paladin Energy Ltd (OtherPALAF)

TIPRANKS
·
Jan 22

California Resources Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 22